Product Description
Mechanisms of Action: Adenylosuccinate Synthase Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: National Cancer Institute (NCI)
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Lung Cancer|Sarcoma|Pancreatic Cancer|Mesothelioma
Phase 1: Glioma|Brain Stem Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SALMEDIX-SDX-102-01 | P2 |
Completed |
Sarcoma|Lung Cancer|Mesothelioma|Pancreatic Cancer |
2005-12-01 |
|
| CDR0000349473 | P1 |
Completed |
Glioma|Brain Stem Cancer |
None |